Vaccine Types and Rational Vaccine Design

Vaccines differ not only in which virus they target but in how the antigen is presented to the immune system — as a weakened live virus, a killed preparation, a purified protein, a gene-delivering vector, or messenger RNA. Rational vaccine design selects and engineers the antigen and platform to elicit a protective response, increasingly guided by structural knowledge of the viral proteins involved.

Definition

Vaccine design is the selection of a viral antigen and a delivery platform — together with any adjuvant — engineered to induce protective, durable adaptive immunity while remaining safe, with platforms ranging from whole attenuated or inactivated virus to subunit proteins and nucleic-acid constructs.

Scope

This topic covers the major vaccine platforms (live-attenuated, inactivated, subunit and conjugate, viral-vector, and nucleic-acid), the role of adjuvants, and the principles of rational and structure-based design. It explains how each platform shapes the resulting immune response. It does not address schedules, indications, or individual immunization advice.

Core questions

• What are the main vaccine platforms and how do they differ mechanistically?
• Why does platform choice influence the strength, breadth, and durability of immunity?
• What is an adjuvant and when is one needed?
• How does structural knowledge of viral antigens enable rational design?
• What trade-offs exist between live, inactivated, and nucleic-acid approaches?

Key concepts

• Live-attenuated vaccines
• Inactivated (killed) vaccines
• Subunit and conjugate vaccines
• Viral-vector vaccines
• Nucleic-acid (mRNA and DNA) vaccines
• Adjuvants
• Antigen selection and immunogen design
• Structure-based and rational vaccine design

Mechanisms

Each platform delivers viral antigen by a different route. Live-attenuated vaccines use a weakened but replicating virus that mimics natural infection and tends to induce broad, durable immunity; inactivated vaccines present non-replicating whole virus and often require boosting and adjuvants. Subunit and conjugate vaccines use purified proteins or polysaccharides, trading breadth for safety. Viral-vector and nucleic-acid vaccines instead deliver the genetic instructions for an antigen so the recipient's own cells produce it, engaging both antibody and T-cell responses. Pollard and Bijker (2020) provide the comparative framework for these platforms, and Shi et al. (2019) describe how adjuvants enhance and shape the response to non-live antigens. Rational design refines the antigen itself — for example stabilizing a viral surface protein in its prefusion conformation — to focus immunity on protective epitopes.

Clinical relevance

Platform choice determines much of a vaccine's practical profile — how it is stored, how many doses are needed, and the type of immunity it favours — which is why understanding the platforms is central to interpreting vaccine evidence. The large COVID-19 mRNA vaccine trials (Polack et al., 2020; Baden et al., 2021) demonstrated a then-new platform reaching high measured efficacy. This entry explains the science of these designs and is not a source of immunization recommendations.

History

Vaccine design progressed from Jenner's whole-pathogen inoculation through Pasteur's attenuation, to mid-twentieth-century inactivated and live viral vaccines, then to subunit and recombinant antigens, and finally to viral-vector and mRNA platforms that reached licensure during the COVID-19 pandemic, as charted by Pollard and Bijker (2020).

Debates

Do nucleic-acid and vector platforms supersede traditional whole-virus vaccines?

Newer platforms offer speed and flexibility and proved highly effective against SARS-CoV-2, but live and inactivated vaccines retain advantages in some settings, so the field treats platform choice as antigen- and context-dependent rather than settled.

Key figures

• Andrew Pollard
• Stanley Plotkin

Seminal works

• pollard-bijker-2020
• shi-2019

Frequently asked questions

What is the difference between a subunit vaccine and an mRNA vaccine?

A subunit vaccine delivers a ready-made viral protein, while an mRNA vaccine delivers the genetic instructions so the recipient's own cells make the protein; both aim to present the same antigen but reach it by different routes.

Why do some vaccines contain an adjuvant?

Purified or inactivated antigens are often weakly immunogenic on their own, so an adjuvant is added to stimulate and shape the immune response, improving the strength and durability of protection.